Thematic area:
Decision Support & Clinical Pathway Innovation
Product:
A low cost, whistle-based respiratory screening device that uses smartphone captured acoustic signatures to estimate airflow, FVC, and lung elasticity. It provides a portable alternative to traditional spirometers for early, widescale lung function assessment.
Market:
Targets the global spirometry and remote lung monitoring market, worth ~$2B and growing due to increasing prevalence of asthma, COPD, and post-COVID 19 respiratory disease. Ideal customers include primary care services, lung cancer screening programmes, pharmacies, and low resource health settings.
Fit:
Current spirometry is costly, labour intensive, and often inaccessible. This device fills a global unmet need for ultralow cost, mass deployed respiratory screening, offering potential to scale to millions of users. Strong IP potential and clinical validation opportunities position it well for spinout formation.
